Global Cancer Diagnostics Partnering Deal Terms and and Agreement Analysis Report 2023: Access to Over 900 - Access to Company A-Z, Headline, Upfront, Milestone, Upfront and Royalty Data
2023-06-22
DUBLIN, June 22, 2023 /PRNewswire/ -- The "Global Cancer Diagnostics Partnering Terms and Agreements 2016-2023" report has been added to
ResearchAndMarkets.com's offering.
This report provides details of the latest cancer diagnostics agreements announced in the life sciences since 2016.
The report presents financial deal term values for cancer diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
One of the key highlights of the report is that over 900 online deal records of actual cancer diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of cancer diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer diagnostics dealmaking since 2016, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading cancer diagnostics deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides a comprehensive and detailed review of cancer diagnostics partnering deals signed and announced since Jan 2016, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of cancer diagnostics partnering deals signed and announced since Jan 2016. The chapter is organized by specific cancer diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by cancer diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer diagnostics technologies and products.
Key benefits
Global Cancer DiagnosticsCancer Diagnostics Partnering Terms and Agreements 2016-2023 provides the reader with the following key benefits:
In-depth understanding of cancer diagnostics deal trends since 2016
Access to headline, upfront, milestone and royalty data
Detailed access to actual cancer diagnostics contracts entered into by leading biopharma companies
Identify most active cancer diagnostics dealmakers since 2016
Insight into terms included in a cancer diagnostics partnering agreement, with real world examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
In Global Cancer DiagnosticsCancer Diagnostics Partnering Terms and Agreements 2016-2023, the available deals are listed by:
Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Technology type
Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Partial list of companies featured
Aetna
Angle
Axela
Bayer
Ceres
COTA
CSIRO
Cypre
D-Eye
Dako
Eigen
Fscan
Grail
IBM
iCAD
IPMD
Item
KEW
Lab21
Mavig
NASA
Ochin
Orot+
RAW
Sebia
Seer
Take2
UPMC
For more information about this report visit https://www.researchandmarkets.com/r/dy2tsi
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。